What we're reading, November 25, 2015: UnitedHealthcare's decision on healthcare exchange participation, Democratic Presidential candidate's health plan, and conflict of interest between soda company and anti-obesity research group.
Does UnitedHealthcare’s Decision Spell ACA Trouble or Business Gimmick?
UnitedHealthcare’s recent announcement of withdrawal from the Affordable Care Act’s health exchanges, effective 2017, resulted in a flurry of reports questioning the performance of these individual marketplace exchanges. The disclosure by UnitedHealth Group Inc, which had just last month sounded optimistic notes about the segment’s prospects, is the latest sign that many insurers are finding the new business unprofitable, despite an influx of customers that has helped swell revenues, reported The Wall Street Journal. However, the answer could be much more complicated according to a Brookings blog.
Read here.
Democratic Presidential Candidate Details Health Plan for When Elected
Following on the footsteps of the other Democratic Presidential candidates, Bernie Sanders and Hillary Clinton, Governor Martin O’Malley has announced his vision for revamping the healthcare system of the country. Released on Tuesday, the health plan promises to address rising drug costs, price transparency, shift from fee-for-service, as well as pharmaceutical mergers based on improving tax rates.
Read here.
Coke Interfered With Work of Anti-Obesity Group, E-Mails Reveal
While the Global Energy Balance Network, led by a professor at the University of Colorado, claims that Coke did nothing beyond providing $1.5 million in funding for the research group, The Associate Press (AP) has evidence proving otherwise. A report published by AP shaped not just the leadership of the group, but also its mission statement and suggested articles and videos for its website.
Read here.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Lifestyle Interventions, Statins, Among Keys to Mitigating CVD Risk in MASLD/MASH
April 15th 2025A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated steatohepatitis (MASH) and looks ahead to the future promise of glucagon-like peptide 1 (GLP-1) receptor agonists for liver conditions.
Read More